Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Deerfield and The Johns Hopkins University Announce Collaboration to Catalyze Early Stage Therapeutic Research

New York, NY and Baltimore, MD – November 16, 2017 – Deerfield Management and The Johns Hopkins University announced today the creation of Bluefield Innovations, a collaboration designed to catalyze the development of early stage therapeutics. Funded by Deerfield, an investment management firm committed to advancing healthcare, Bluefield Innovations will provide up to $65 million in initial funding over five years to support the commercialization of early stage therapeutic research at Johns Hopkins, with additional funding available to advance research showing strong commercial potential.

A joint steering committee will identify the research that Bluefield will support through the preclinical development process — including basic research, proof of concept, target selection and investigational new drug (IND) enabling studies designed to qualify a candidate to enter into human clinical trials. Research developed within Bluefield will either be licensed to third parties or spun out into new companies. Funding for companies supported by Bluefield may include capital from Deerfield.

“We are proud and excited to be collaborating with Johns Hopkins, a premier institution with world-class scientists dedicated to pushing the boundaries of discovery to transform healthcare,” stated James Flynn, Managing Partner at Deerfield Management. “Further, the development expertise and scientific leadership resident at Johns Hopkins Drug Discovery Program is a tremendous asset in enabling Bluefield to move the innovations of Hopkins’ scientists forward toward their therapeutic applications.”

Combining the respective strengths of each organization — Johns Hopkins’ scientific discovery expertise and Deerfield’s drug development, operational and financial support — enables Bluefield to reduce the financial and developmental risk associated with early stage novel projects.

“For more than 125 years, Johns Hopkins has been at the forefront of research and medical innovation. As we expand this tradition, collaborations with industry will help us more efficiently move groundbreaking technologies to market,” said Ronald J. Daniels, president of The Johns Hopkins University. “Our relationship with Deerfield will provide a fully funded and professionally supported avenue for Johns Hopkins researchers to deliver on the potential of their promising work.”

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visitwww.deerfield.com.

Contacts

Deerfield Management Company
Karen Heidelberger, 212-551-1600
[email protected]